Iocetamic acid, a synthetic analog of iodoacetic acid, is a potent inhibitor of glycolysis. It inhibits the enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a key enzyme in glycolysis, by covalently binding to its active site. This inhibition disrupts the production of ATP, a critical energy source for cells. Research on iocetamic acid has focused on its potential as an anti-cancer agent. Studies have shown that it can suppress the growth of cancer cells, likely by inhibiting their glycolytic metabolism. However, its toxicity and limited bioavailability have hindered its clinical development. Despite this, the study of iocetamic acid continues to provide valuable insights into the role of glycolysis in cancer cell survival and offers a starting point for the development of new anti-cancer drugs that target glycolytic pathways.'
iocetamic acid: was MH 1975-92 (see under IODOBENZENES 1975-90); use IODOBENZENES to search IOCETAMIC ACID 1975-92 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 27648 |
| CHEMBL ID | 1200770 |
| CHEBI ID | 91662 |
| SCHEMBL ID | 38499 |
| MeSH ID | M0198136 |
| Synonym |
|---|
| MLS002154025 |
| smr001233352 |
| BRD-A37492983-001-03-8 |
| iocetamic acid |
| 3-[acetyl(3-amino-2,4,6-triiodophenyl)amino]-2-methylpropanoic acid |
| BSPBIO_000795 |
| PRESTWICK3_000838 |
| drc 1201 |
| hsdb 3344 |
| cholebrine |
| brn 2171366 |
| acide iocetamique [inn-french] |
| beta-alanine, n-acetyl-n-(3-amino-2,4,6-triiodophenyl)-2-methyl- |
| 3-(acetyl-(3-amino-2,4,6-triiodophenyl)amino)-2-methylpropanoic acid |
| n-acetyl-n-(2,4,6-triiodo-3-aminophenyl)-beta-aminoisobutyric acid |
| n-acetyl-n-(3-amino-2,4,6-triiodophenyl)-2-methyl-beta-alanine |
| acidum jocetamicum |
| n-acetyl-n-(3-amino-2,4,6-triiodophenl)-2-methyl-beta-alanine |
| propionic acid, 3-(acetyl-(3-amino-2,4,6-triiodophenyl)amino)-2-methyl- |
| colebrina |
| mp 620 |
| acido iocetamico [inn-spanish] |
| acidum iocetamicum [inn-latin] |
| propanoic acid, 3-(acetyl(3-amino-2,4,6-triiodophenyl)amino)-2-methyl- |
| n-acetyl-n-(3-amino-2,4,6-triiodophenyl)-beta-aminoisobutyric acid |
| cholimil |
| einecs 240-173-1 |
| cas-16034-77-8 |
| NCGC00016720-01 |
| NCGC00179430-01 |
| iocetamic acid (usan) |
| cholebrine (tn) |
| 16034-77-8 |
| D04563 |
| PRESTWICK2_000838 |
| AB00513935 |
| BPBIO1_000875 |
| SPBIO_002716 |
| PRESTWICK0_000838 |
| PRESTWICK1_000838 |
| CHEMBL1200770 |
| mp-620 |
| HMS1570H17 |
| 3-(n-acetyl-3-amino-2,4,6-triiodoanilino)-2-methylpropanoic acid |
| HMS2097H17 |
| acidum iocetamicum |
| acide iocetamique |
| fa675q0e3e , |
| acido iocetamico |
| iocetamic acid [usan:usp:inn:ban] |
| unii-fa675q0e3e |
| dtxcid303149 |
| dtxsid2023149 , |
| tox21_110580 |
| HMS2234P18 |
| iocetamic acid [mi] |
| iocetamic acid [inn] |
| iocetamic acid [mart.] |
| iocetamic acid [vandf] |
| iocetamic acid [who-dd] |
| iocetamic acid [orange book] |
| iocetamic acid [hsdb] |
| iocetamic acid [usan] |
| HMS3373O18 |
| CCG-220838 |
| SCHEMBL38499 |
| SR-01000838894-2 |
| sr-01000838894 |
| CHEBI:91662 |
| 3-(n-(3-amino-2,4,6-triiodophenyl)acetamido)-2-methylpropanoic acid |
| HMS3714H17 |
| Q6062203 |
| DB09403 |
| cholimil; drc 1201; iocetamic acid; mp 620 |
| NCGC00179430-04 |
| EN300-18568455 |
| 3-[n-(3-amino-2,4,6-triiodophenyl)acetamido]-2-methylpropanoic acid |
| STARBLD0009604 |
| CS-0030997 |
| acido iocetamico (inn-spanish) |
| iocetamic acid (usan:usp:inn:ban) |
| acidum iocetamicum (inn-latin) |
| iocetamic acid (mart.) |
| acide iocetamique (inn-french) |
| HY-107957 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Class | Description |
|---|---|
| aromatic amide | An amide in which the amide linkage is bonded directly to an aromatic system. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 2.8184 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 1.8356 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 8.9125 | 0.0096 | 10.5250 | 35.4813 | AID1479145 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 22.3872 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| RNA polymerase II cis-regulatory region sequence-specific DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| double-stranded DNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| RNA binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| mRNA 3'-UTR binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| lipid binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| identical protein binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| pre-mRNA intronic binding | TAR DNA-binding protein 43 | Homo sapiens (human) |
| molecular condensate scaffold activity | TAR DNA-binding protein 43 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| virion membrane | Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus |
| intracellular non-membrane-bounded organelle | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleus | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
| perichromatin fibrils | TAR DNA-binding protein 43 | Homo sapiens (human) |
| mitochondrion | TAR DNA-binding protein 43 | Homo sapiens (human) |
| cytoplasmic stress granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nuclear speck | TAR DNA-binding protein 43 | Homo sapiens (human) |
| interchromatin granule | TAR DNA-binding protein 43 | Homo sapiens (human) |
| nucleoplasm | TAR DNA-binding protein 43 | Homo sapiens (human) |
| chromatin | TAR DNA-binding protein 43 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.81) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||